Jonathan Lim
Showing 1–2 of 2 transcripts.
- a16z27 min
Biotech CEO on where we are in the fight to cure cancer
Former Halozyme CEO Jonathan Lim leverages his experience scaling biotech startups to lead Araska Therapeutics, a company targeting the historically undruggable RAS pathway with a pipeline including the pan-RAF inhibitor Naporafenib. Concurrently, his family office, City Hill Ventures, manages a diversified portfolio of life sciences assets and media projects that parallel the high-risk, high-reward dynamics of pharmaceutical development. Lim's strategy emphasizes capital preservation and the combination of novel molecular glues with standard therapies to drive long-term remission rates beyond current limits in pancreatic, lung, and colon cancers.
- a16z16 min
The 5 Revolutions in Cancer Treatment
Jonathan Lim, Patrick, Jimmy Carter
Drawing on personal loss and a career launching seven approved oncology products, the speaker argues that eradicating cancer requires integrating five distinct revolutions: surgery and radiation, genomically targeted therapy, immunotherapy, the targeting of extra-chromosomal DNA, and metabolic interventions. While highlighting breakthroughs such as the recovery of metastatic patients via drugs like Entrectinib and Keytruda, the presentation emphasizes that current single-modality approaches fail to address the complexity of advanced disease or the role of factors like ecDNA and nutrition. Ultimately, the event advocates for a personalized, multimodal strategy that combines these scientific advances to improve long-term survival rates beyond the current limits of one-third of patients.